Vanucizumab

Last updated
Vanucizumab
Monoclonal antibody
Type Whole antibody
Source Humanized
Target angiopoietin 2
Clinical data
Other namesRG7221
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6529H10033N1733O2038S46
Molar mass 146887.94 g·mol−1

Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer. [1] [2]

Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.[ citation needed ]

This drug was developed by Genentech/Roche.[ citation needed ]

Related Research Articles

An international nonproprietary name (INN) is an official generic and nonproprietary name given to a pharmaceutical drug or an active ingredient. INNs are intended to make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors. The INN system has been coordinated by the World Health Organization (WHO) since 1953.

The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.

<span class="mw-page-title-main">Mertansine</span> Chemical compound

Mertansine, also called DM1, is a thiol-containing maytansinoid that for therapeutic purposes is attached to a monoclonal antibody through reaction of the thiol group with a linker structure to create an antibody-drug conjugate (ADC).

Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. Under the INN system, generic names for drugs are constructed out of affixes and stems that classify the drugs into useful categories while keeping related names distinguishable. A marketed drug might also have a company code or compound code.

Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator.

Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.

Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis. It binds to IL17A and acts as an immunomodulator.

Abrilumab is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.

Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC

Lulizumab pegol is a monoclonal antibody designed for the treatment of autoimmune diseases.

Pinatuzumab vedotin is a monoclonal antibody designed for the treatment of B-cell malignancies.

Seribantumab is a monoclonal antibody designed for the treatment of cancer.

Brontictuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Lumretuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Plozalizumab is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.

Cofetuzumab pelidotin is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.

Mirikizumab is a human monoclonal antibody designed for the treatment of psoriasis.

<span class="mw-page-title-main">Faricimab</span> Medication for macular degeneration

Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor (VEGF), and angiopoietin 2 (Ang-2) inhibitor. By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection by an ophthalmologist.

Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats.

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association .
  2. ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.